Drug Details

General Information of the Drug (ID: DR6061)
Name
Lenalidomide
Synonyms
Lenalidomide; 191732-72-6; Revlimid; Revimid; 3-(4-Amino-1-oxoisoindolin-2-yl)piperidine-2,6-dione; CC-5013; Lenalidomide (CC-5013); CDC 501; IMiD3; CC 5013; CDC-501; 3-(4-Amino-1-oxo-1,3-dihydro-2H-isoindol-2-yl)piperidine-2,6-dione; 2,6-Piperidinedione, 3-(4-amino-1,3-dihydro-1-oxo-2H-isoindol-2-yl)-; 3-(7-amino-3-oxo-1H-isoindol-2-yl)piperidine-2,6-dione; Revlimid (TN); CHEBI:63791; C13H13N3O3; MFCD07772307; 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-aminoisoindoline; NCGC00167491-01; 3-(4-amino-1-oxo-2,3-dihydro-1H-isoindol-2-yl)piperidine-2,6-dione; DSSTox_CID_26664; DSSTox_RID_81806; DSSTox_GSID_46664; Revlimid (lenalidomide); 3-(4-Amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione; CAS-191732-72-6; Lenalidomide (USAN/INN); Lenadoamide; Lenalidomide [USAN:INN:BAN]; (3S)-3-(4-Amino-1-oxo-1,3-dihydro-2H-isoindol-2-yl)piperidine-2,6-dione; ENMD 0997; ENMD-0997; HSDB 8220; IMID-5013; CDC-5013; ALBB-015321; 1227162-34-6; PubChem19113; CHEMBL848; Revlimid (TN) (Celgene); SCHEMBL32978; MLS003899194; GTPL7331; SCHEMBL1980410; 3-(4-Amino-1-oxo-2-isoindolinyl)piperidine-2,6-dione; DTXSID8046664; BDBM65454; 2,6-piperidinedione, 3-(4-amino-1,3-dihydro-1-oxo-2H-isoindol-2-yl)-, (3S)-; 3-(7-Amino-3-oxo-1H-isoindol-2-yl)-piperidine-2,6-dione; BCPP000186; HMS3654G07; HMS3674C05; BCP01390; HY-A0003; Revlimid, Lenalidomide, CC-5013; SYP-1512; Tox21_112492; ABP001089; AC-914; NSC747972; s1029; STK639603; 2,6-Piperidinedione, 3-(4-amino-1,3-dihydro-1-oxo-2H- isoindol-2-yl)-; AKOS005146276; AKOS005174869; Tox21_112492_1; ACN-034469; BCP9000847; CCG-264781; CS-0125; DB00480; KS-1207; MCULE-9771679074; NSC 747972; NSC-747972; NCGC00167491-02; NCGC00167491-03; NCGC00167491-04; AK-47482; SMR002529986; SY047646; AB0017965; AM20050439; FT-0659651; FT-0670758; FT-0670759; SW218084-2; T5245; EC-000.2340; D04687; S-4172; AB01273975-01; AB01273975-02; AB01273975_03; 732L726; Q425681; SR-01000883999; Q-101410; SR-01000883999-1; Z1741976709; 2, 3-(4-amino-1,3-dihydro-1-oxo-2H-isoindol-2-yl)-; 3-(4-amino-1,3-dihydro-1-oxo-2h-isoindol-2-yl)-2,6-piperidinedione; 3-(4-amino-1-oxo-1,3-dihydro-2H-isoindol-2-yl)-2,6-dioxopiperidine; 3-(4-Amino-1-oxo-1,3-dihydro-2H-isoindol-2-yl)-2,6-piperidinedione; 4-amino-2-(6-hydroxy-2-oxo-2,3,4,5-tetrahydropyridin-3-yl)-2,3-dihydro-1H-isoindol-1-one; 443912-14-9
    Click to Show/Hide
Molecular Type
Small molecule
Disease Multiple myeloma [ICD-11: 2A83] Approved [1]
Structure
Click to Download Mol
2D MOL

3D MOL

    Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product
Formula
C13H13N3O3
PubChem CID
216326
Canonical SMILES
C1CC(=O)NC(=O)C1N2CC3=C(C2=O)C=CC=C3N
InChI
1S/C13H13N3O3/c14-9-3-1-2-7-8(9)6-16(13(7)19)10-4-5-11(17)15-12(10)18/h1-3,10H,4-6,14H2,(H,15,17,18)
InChIKey
GOTYRUGSSMKFNF-UHFFFAOYSA-N
CAS Number
CAS 191732-72-6
ChEBI ID
CHEBI:63791
TTD Drug ID
D0Q5NX
DrugBank ID
DB00480
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally
    α. A List of Natural Product(s) Able to Enhance the Efficacy of This Drug
          Arsenic trioxide      Realgar and orpiment     Click to Show/Hide the Molecular Data of This NP
                 Achieving Therapeutic Synergy     Click to Show/Hide
                    Representative Experiment Reporting the Effect of This Combination [2]
                    Detail(s)  Combination Info  click to show the detail info of this combination
                    Molecule(s)
                    Regulation		 Up-regulation Cleavage CASP3  Molecule Info 
Pathway MAP
Down-regulation Expression IL10  Molecule Info 
Pathway MAP
Down-regulation Expression IL6  Molecule Info 
Pathway MAP
Down-regulation Phosphorylation NFKBIA  Molecule Info 
Pathway MAP
                    In-vitro Model BC-3 CVCL_1080 Primary effusion lymphoma Homo sapiens
BCBL-1 CVCL_0165 Primary effusion lymphoma Homo sapiens
                    In-vivo Model Six to eight week old immuno-compromised male or female NOD/SCID mice were inoculated with 2 million BC-3 or BCBL-1 cells.
                    Experimental
                    Result(s)		 Lenalidomide in combination with arsenic trioxide is an effective therapy for primary effusion lymphoma.
          Tanshinone I      Salvia miltiorrhiza     Click to Show/Hide the Molecular Data of This NP
                 Achieving Therapeutic Synergy     Click to Show/Hide
                    Representative Experiment Reporting the Effect of This Combination [3]
                    Detail(s)  Combination Info  click to show the detail info of this combination
                    Molecule(s)
                    Regulation		 Down-regulation Expression ACD  Molecule Info 
Pathway MAP
Down-regulation Expression TERF2IP  Molecule Info 
Pathway MAP
Down-regulation Expression TNKS-1  Molecule Info 
Pathway MAP
                    In-vitro Model RPMI-8226 CVCL_0014 Plasma cell myeloma Homo sapiens
U266B1 CVCL_0566 Plasma cell myeloma Homo sapiens
                    Experimental
                    Result(s)		 Combination of TanI with standard chemotherapeutic drug Len, potentiates cell death in myeloma cells.
Target and Pathway
Target(s) Tumor necrosis factor (TNF)  Molecule Info  [4]
KEGG Pathway MAPK signaling pathway Click to Show/Hide
2 Cytokine-cytokine receptor interaction
3 NF-kappa B signaling pathway
4 Sphingolipid signaling pathway
5 mTOR signaling pathway
6 Apoptosis
7 TGF-beta signaling pathway
8 Osteoclast differentiation
9 Antigen processing and presentation
10 Toll-like receptor signaling pathway
11 NOD-like receptor signaling pathway
12 RIG-I-like receptor signaling pathway
13 Hematopoietic cell lineage
14 Natural killer cell mediated cytotoxicity
15 T cell receptor signaling pathway
16 Fc epsilon RI signaling pathway
17 TNF signaling pathway
18 Adipocytokine signaling pathway
19 Type II diabetes mellitus
20 Non-alcoholic fatty liver disease (NAFLD)
21 Type I diabetes mellitus
22 Alzheimer's disease
23 Amyotrophic lateral sclerosis (ALS)
24 Pertussis
25 Legionellosis
26 Leishmaniasis
27 Chagas disease (American trypanosomiasis)
28 African trypanosomiasis
29 Malaria
30 Toxoplasmosis
31 Amoebiasis
32 Tuberculosis
33 Hepatitis C
34 Hepatitis B
35 Influenza A
36 HTLV-I infection
37 Herpes simplex infection
38 Proteoglycans in cancer
39 Asthma
40 Inflammatory bowel disease (IBD)
41 Systemic lupus erythematosus
42 Rheumatoid arthritis
43 Allograft rejection
44 Graft-versus-host disease
45 Hypertrophic cardiomyopathy (HCM)
46 Dilated cardiomyopathy
NetPath Pathway TCR Signaling Pathway Click to Show/Hide
2 IL2 Signaling Pathway
3 IL3 Signaling Pathway
4 IL4 Signaling Pathway
5 Leptin Signaling Pathway
6 RANKL Signaling Pathway
7 IL1 Signaling Pathway
Panther Pathway Apoptosis signaling pathway Click to Show/Hide
2 Wnt signaling pathway
Pathwhiz Pathway Fc Epsilon Receptor I Signaling in Mast Cells Click to Show/Hide
Pathway Interaction Database IL27-mediated signaling events Click to Show/Hide
2 Canonical NF-kappaB pathway
3 Calcineurin-regulated NFAT-dependent transcription in lymphocytes
4 Angiopoietin receptor Tie2-mediated signaling
5 Signaling events mediated by HDAC Class I
6 TNF receptor signaling pathway
7 Ceramide signaling pathway
8 amb2 Integrin signaling
9 RXR and RAR heterodimerization with other nuclear receptor
10 IL23-mediated signaling events
11 HIV-1 Nef: Negative effector of Fas and TNF-alpha
12 Caspase Cascade in Apoptosis
13 Cellular roles of Anthrax toxin
14 Downstream signaling in na&#xef
15
Reactome Transcriptional regulation of white adipocyte differentiation Click to Show/Hide
2 TNFR1-induced proapoptotic signaling
3 Regulation of TNFR1 signaling
4 TNFR1-induced NFkappaB signaling pathway
5 TNFR1-mediated ceramide production
6 TNFR2 non-canonical NF-kB pathway
7 TNF signaling
WikiPathways Toll-like receptor signaling pathway Click to Show/Hide
2 Monoamine Transport
3 SIDS Susceptibility Pathways
4 TGF Beta Signaling Pathway
5 Cytokines and Inflammatory Response
6 MAPK Signaling Pathway
7 EV release from cardiac cells and their functional effects
8 FAS pathway and Stress induction of HSP regulation
9 Apoptosis-related network due to altered Notch3 in ovarian cancer
10 Cardiac Hypertrophic Response
11 Transcriptional Regulation of White Adipocyte Differentiation
12 Aryl Hydrocarbon Receptor
13 Apoptosis
14 Nanoparticle triggered regulated necrosis
15 Amyotrophic lateral sclerosis (ALS)
16 Adipogenesis
17 Allograft Rejection
18 TNF alpha Signaling Pathway
19 TWEAK Signaling Pathway
20 Extrinsic Pathway for Apoptosis
21 Folate Metabolism
22 MicroRNAs in cardiomyocyte hypertrophy
23 Vitamin B12 Metabolism
24 Selenium Micronutrient Network
25 Regulation of toll-like receptor signaling pathway
26 Matrix Metalloproteinases
References
Reference 1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7331).
Reference 2 Lenalidomide in Combination with Arsenic Trioxide: an Effective Therapy for Primary Effusion Lymphoma. Cancers (Basel). 2020 Sep 1;12(9):2483.
Reference 3 Novel combination of tanshinone I and lenalidomide induces chemo-sensitivity in myeloma cells by modulating telomerase activity and expression of shelterin complex and its associated molecules. Mol Biol Rep. 2018 Dec;45(6):2429-2439.
Reference 4 Thalidomide and thalidomide analogues for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev. 2009 Apr 15;(2):CD007351.
 Download Picture         KEGG Link      
 Download Picture         KEGG Link      
 Download Picture         KEGG Link      
 Download Picture         KEGG Link      
 Download Picture         KEGG Link      
 Download Picture         KEGG Link      
 Download Picture         KEGG Link